These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 19038289)
1. Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection. Di Lullo G; Soprana E; Panigada M; Palini A; Erfle V; Staib C; Sutter G; Siccardi AG J Virol Methods; 2009 Mar; 156(1-2):37-43. PubMed ID: 19038289 [TBL] [Abstract][Full Text] [Related]
2. The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use. Di Lullo G; Soprana E; Panigada M; Palini A; Agresti A; Comunian C; Milani A; Capua I; Erfle V; Siccardi AG J Virol Methods; 2010 Feb; 163(2):195-204. PubMed ID: 19778556 [TBL] [Abstract][Full Text] [Related]
3. [Design and construction of transfer vectors in order to obtain recombinant modified vaccinia virus Ankara (MVA)]. Ferrer MF; Zanetti FA; Calamante G Rev Argent Microbiol; 2007; 39(3):138-42. PubMed ID: 17987847 [TBL] [Abstract][Full Text] [Related]
4. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Carroll MW; Moss B Virology; 1997 Nov; 238(2):198-211. PubMed ID: 9400593 [TBL] [Abstract][Full Text] [Related]
5. Joint production of prime/boost pairs of Fowlpox Virus and Modified Vaccinia Ankara recombinants carrying the same transgene. Soprana E; Panigada M; Knauf M; Radaelli A; Vigevani L; Palini A; Villa C; Malnati M; Cassina G; Kurth R; Norley S; Siccardi AG J Virol Methods; 2011 Jun; 174(1-2):22-8. PubMed ID: 21419167 [TBL] [Abstract][Full Text] [Related]
6. Marker rescue of the host range restriction defects of modified vaccinia virus Ankara. Wyatt LS; Carroll MW; Czerny CP; Merchlinsky M; Sisler JR; Moss B Virology; 1998 Nov; 251(2):334-42. PubMed ID: 9837798 [TBL] [Abstract][Full Text] [Related]
7. Construction and isolation of recombinant MVA. Staib C; Drexler I; Sutter G Methods Mol Biol; 2004; 269():77-100. PubMed ID: 15114009 [TBL] [Abstract][Full Text] [Related]
8. Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Staib C; Drexler I; Ohlmann M; Wintersperger S; Erfle V; Sutter G Biotechniques; 2000 Jun; 28(6):1137-42, 1144-6, 1148. PubMed ID: 10868279 [TBL] [Abstract][Full Text] [Related]
9. Functional F11L and K1L genes in modified vaccinia virus Ankara restore virus-induced cell motility but not growth in human and murine cells. Zwilling J; Sliva K; Schwantes A; Schnierle B; Sutter G Virology; 2010 Sep; 404(2):231-9. PubMed ID: 20627347 [TBL] [Abstract][Full Text] [Related]
10. Easy and efficient protocols for working with recombinant vaccinia virus MVA. Kremer M; Volz A; Kreijtz JH; Fux R; Lehmann MH; Sutter G Methods Mol Biol; 2012; 890():59-92. PubMed ID: 22688761 [TBL] [Abstract][Full Text] [Related]
11. [Construction and biological characteristic for the recombinant modified vaccinia virus ankara co-expressing modified GP5 and M protein of porcine reproductive and respiratory syndrome virus]. Zheng Q; Li P; Cao R; Hou J; Chen P Sheng Wu Gong Cheng Xue Bao; 2008 May; 24(5):766-73. PubMed ID: 18724695 [TBL] [Abstract][Full Text] [Related]
12. High level protein expression in mammalian cells using a safe viral vector: modified vaccinia virus Ankara. Hebben M; Brants J; Birck C; Samama JP; Wasylyk B; Spehner D; Pradeau K; Domi A; Moss B; Schultz P; Drillien R Protein Expr Purif; 2007 Dec; 56(2):269-78. PubMed ID: 17892951 [TBL] [Abstract][Full Text] [Related]
13. Engineering recombinant poxviruses using a compact GFP-blasticidin resistance fusion gene for selection. Wong YC; Lin LC; Melo-Silva CR; Smith SA; Tscharke DC J Virol Methods; 2011 Jan; 171(1):295-8. PubMed ID: 21073901 [TBL] [Abstract][Full Text] [Related]
14. Dominant host range selection of vaccinia recombinants by rescue of an essential gene. Holzer GW; Gritschenberger W; Mayrhofer JA; Wieser V; Dorner F; Falkner FG Virology; 1998 Sep; 249(1):160-6. PubMed ID: 9740787 [TBL] [Abstract][Full Text] [Related]
15. High Frequency of Homologous Recombination in the Genome of Modified Vaccinia Virus Ankara Strain (MVA). Zhu LX; Xie YH; Li GD; Wang Y Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2001; 33(5):497-503. PubMed ID: 12040389 [TBL] [Abstract][Full Text] [Related]
16. Complementation of a vaccinia virus host-range K1L gene deletion by the nonhomologous CP77 gene. Ramsey-Ewing AL; Moss B Virology; 1996 Aug; 222(1):75-86. PubMed ID: 8806489 [TBL] [Abstract][Full Text] [Related]
17. Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome. Cottingham MG; Gilbert SC J Virol Methods; 2010 Sep; 168(1-2):233-6. PubMed ID: 20417665 [TBL] [Abstract][Full Text] [Related]
18. Defective vaccinia virus as a biologically safe tool for the overproduction of recombinant human secretory proteins. Himly M; Pfleiderer M; Holzer G; Fischer U; Hannak E; Falkner FG; Dorner F Protein Expr Purif; 1998 Dec; 14(3):317-26. PubMed ID: 9882565 [TBL] [Abstract][Full Text] [Related]
19. [A novel double expression shuttle vector to get marker-free recombinant modified vaccinia virus Ankara]. Zheng Q; Bi Z; Li M; Hou J; Chen P Sheng Wu Gong Cheng Xue Bao; 2011 Jun; 27(6):926-34. PubMed ID: 22034822 [TBL] [Abstract][Full Text] [Related]
20. Vectors for recombinational cloning and gene expression in mammalian cells using modified vaccinia virus Ankara. Pradeau-Aubreton K; Ruff M; Garnier JM; Schultz P; Drillien R Anal Biochem; 2010 Sep; 404(1):103-5. PubMed ID: 20450873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]